



Associations between unprocessed red and processed meat, poultry, seafood and egg intake and the risk of prostate cancer: A pooled analysis of 15 prospective cohort studies

Citation

Wu, Kana, Donna Spiegelman, Tao Hou, Demetrius Albanes, Naomi E. Allen, Sonja I. Berndt, Piet A. van den Brandt, et al. 2016. "Associations between Unprocessed Red and Processed Meat, Poultry, Seafood and Egg Intake and the Risk of Prostate Cancer: A Pooled Analysis of 15 Prospective Cohort Studies." *International Journal of Cancer* 138 (10): 2368–82. <https://doi.org/10.1002/ijc.29973>.

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:41292468>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)



Published in final edited form as:

Int J Cancer. 2016 May 15; 138(10): 2368–2382. doi:10.1002/ijc.29973.

Associations between unprocessed red and processed meat, poultry, seafood and egg intake and the risk of prostate cancer: A pooled analysis of 15 prospective cohort studies

Kana Wu¹, Donna Spiegelman^{2,3}, Tao Hou¹, Demetrius Albanes⁴, Naomi E. Allen⁵, Sonja I. Berndt⁴, Piet A. van den Brandt⁶, Graham G. Giles^{7,8}, Edward Giovannucci^{1,2,9}, R. Alexandra Goldbohm¹⁰, Gary G. Goodman¹¹, Phyllis J. Goodman¹², Niclas Håkansson¹³, Manami Inoue¹⁴, Timothy J. Key¹⁵, Laurence N. Kolonel¹⁶, Satu Männistö¹⁷, Marjorie L. McCullough¹⁸, Marian L. Neuhouser¹¹, Yikyung Park¹⁹, Elizabeth A. Platz²⁰, Jeannette M. Schenk²¹, Rashmi Sinha⁴, Meir J. Stampfer^{1,2,9}, Victoria L. Stevens¹⁸, Shoichiro Tsugane¹⁴, Kala Visvanathan²⁰, Lynne R. Wilkens¹⁶, Alicja Wolk¹³, Regina G. Ziegler⁴, and Stephanie A. Smith-Warner^{1,2}

¹Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA ²Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA ³Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA ⁴Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD ⁵Nuffield Department of Population Health, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, United Kingdom ⁶Department of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands ⁷Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Victoria, Australia ⁸Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia ⁹Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA ¹⁰Department of Food and Chemical Risk Analysis, TNO Quality of Life, Zeist, The Netherlands ¹¹Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA ¹²SWOG Statistical Center, Seattle, WA ¹³Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden ¹⁴Epidemiology and Prevention Group, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan ¹⁵Nuffield Department of Population Health, Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom ¹⁶Department of Epidemiology, Cancer Research Center, University of Hawaii, Honolulu, HI ¹⁷Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland ¹⁸Epidemiology Research Program, American Cancer Society, Atlanta, GA ¹⁹Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO ²⁰Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD ²¹Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington

Correspondence to: Kana Wu, 665 Huntington Avenue, Boston, MA 02115, USA, Tel.: 617-432-1842, Fax: 617-432-2435, kana.wu@channing.harvard.edu.

Additional Supporting Information may be found in the online version of this article

Abstract

Reports relating meat intake to prostate cancer risk are inconsistent. Associations between these dietary factors and prostate cancer were examined in a consortium of 15 cohort studies. During follow-up, 52,683 incident prostate cancer cases, including 4,924 advanced cases, were identified among 842,149 men. Cox proportional hazard models were used to calculate study-specific relative risks (RR) and then pooled using random effects models. Results do not support a substantial effect of total red, unprocessed red and processed meat for all prostate cancer outcomes, except for a modest positive association for tumors identified as advanced stage at diagnosis (advanced(*r*)). For seafood, no substantial effect was observed for prostate cancer regardless of stage or grade. Poultry intake was inversely associated with risk of advanced and fatal cancers (pooled multivariable RR [MVR], 95% confidence interval, comparing 45 vs. <5 g/day: advanced 0.83, 0.70–0.99; trend test *p* value 0.29), fatal, 0.69, 0.59–0.82, trend test *p* value 0.16). Participants who ate 25 versus <5 g/day of eggs (1 egg ~ 50 g) had a significant 14% increased risk of advanced and fatal cancers (advanced 1.14, 1.01–1.28, trend test *p* value 0.01; fatal 1.14, 1.00–1.30, trend test *p* value 0.01). When associations were analyzed separately by geographical region (North America vs. other continents), positive associations between unprocessed red meat and egg intake, and inverse associations between poultry intake and advanced, advanced(*r*) and fatal cancers were limited to North American studies. However, differences were only statistically significant for eggs. Observed differences in associations by geographical region warrant further investigation.

Keywords

prostate cancer; diet; unprocessed red meat; processed meat; poultry; seafood; egg

Epidemiological evidence linking meat intake to prostate cancer risk has been inconsistent.^{1,2} One reason for the inconsistencies between studies may be that prostate cancer is a heterogeneous disease and risk factors for indolent prostate cancers differ from those for fatal cancers, while the majority of prostate cancer studies on meat consumption have focused on total prostate cancer. However, in terms of cancer prevention, identification of modifiable risk factors associated with prostate cancers that have lethal potential is more relevant. Furthermore, risk factors that enhance progression of prostate cancers may be independent from those that affect grade, *i.e.* differentiation of prostate cancer.³

We conducted a pooled analysis of the associations between meat and egg intake and prostate cancer risk overall and separately by stage and grade using primary data from 15 cohort studies. Ten of these studies had previously published their results regarding at least one of the dietary factors evaluated and prostate cancer risk.^{4–16} We also examined associations between egg intake and prostate cancer, because eggs are another major source of animal protein and recent evidence suggests that higher egg intake may increase risk of lethal prostate cancer.^{16,17}

Methods

Study population

The Pooling Project of Prospective Studies of Diet and Cancer (DCPP) is a consortium established to examine associations between dietary factors and cancer risk.¹⁸ Fifteen cohorts from North America, Europe, Australia and Asia were included in this pooled analysis (Table 1).^{4,5,7–13,19–23} Each study met the following predefined inclusion criteria: (i) at least one publication on any diet and cancer association, (ii) assessment of long-term diet, (iii) validation of the dietary assessment method or a closely related dietary instrument and (iv) at least 50 incident cases of prostate cancer.¹⁸ The Netherlands Cohort Study was analyzed as a case-cohort study because in that study questionnaires were only processed for cases and a random sample of the cohort.^{18,24} Each study was approved by its respective Institutional Review Board.

Ascertainment of cases

We included primary incident prostate cancer cases. Only deaths where the underlying cause of death was prostate cancer were considered as fatal cases. Advanced cancers were defined as tumors with stage T4, N1, M1 or fatal tumors. In order to account for cases that were initially diagnosed as localized cancers or cases with missing stage data at time of diagnosis, who died during follow-up, a second advanced outcome was defined (“advanced restricted”). The definition of “advanced restricted” (from now on referred to as advanced(*r*)) includes cases known to be advanced at diagnosis *i.e.* T4, N1, M1 or fatal cases after exclusion of fatal cases who were initially diagnosed as localized cases or those with missing stage information at diagnosis. Fatal cases initially diagnosed as localized are likely cases with undetected micro-metastases at diagnosis. High-grade cancers were defined as having Gleason score ≥ 8 or being poorly differentiated/undifferentiated (for more detail please refer to the Supporting Information Appendix).

For the Prostate Cancer Prevention Trial (PCPT)²³ only cases diagnosed through a biopsy performed because of an elevated prostate-specific antigen (PSA) or suspicious digital rectal exam (“for cause”) were included. Further, only participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) assigned to the screened arm were included in this study.⁵

Dietary assessment

Each study provided their primary dietary data, which were collected using baseline self-administered food frequency questionnaires (FFQs)¹⁸ or interviewer-administered quantitative dietary questionnaires at some centers in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.²⁵ The validity of intakes of food groups was not assessed by most cohorts;¹⁸ but cohort-specific correlations comparing the intake estimates by the FFQs *versus* multiple dietary records or 24 h recalls for total fat, saturated fat, total protein or cholesterol (nutrients related to meat and/or egg intake) were generally greater than 0.40.^{18,23,25–31}

For more details regarding how the unprocessed red meat (from now on referred to as red meat), processed meat, poultry, seafood and egg food groups were defined, refer to footnote in Table 2. For three studies, the Japan Public Health Center-Based Study Cohort 1 and 2 and our largest cohort, the NIH AARP Diet and Health Study with 18,889 cases, we were unable to distinguish total shellfish from total fish intake. Thus, results are presented for shellfish and fish intake combined (referred to as seafood). However, four studies (Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, CLUE II: Campaign Against Cancer and Heart Disease, Cancer Prevention Study-II Nutrition Cohort and Netherlands Cohort Study) did not assess shellfish intake therefore seafood intake represents fish intake for those studies.

Assessment of non-dietary risk factors

All studies provided information on age, height and weight at baseline. Most studies assessed smoking habits, physical activity, education, marital status and multivitamin use. Missing information was coded using an indicator variable for the missing category for all measured variables in a study.

Statistical analysis

Participants with a history of cancer (except for non-melanoma skin cancer), with energy intakes beyond three standard deviations from the study-specific \log_e -transformed mean energy intake, or with missing information on the exposure evaluated were excluded from our analyses. Participants contributed person years of follow-up from the date of the baseline questionnaire to the date of diagnosis of prostate cancer, death (for all fatal cases including those with available date of diagnosis) and loss to follow-up, if available, or administrative end of follow-up, whichever came first. Intakes of meat and eggs were modeled as categorical variables using absolute intake cutoffs. The common absolute intake cutoffs were defined *a priori* and were selected to maximize inclusion of data from individual studies in each intake category and to represent increments of generally accepted serving sizes of each item.

We used a two-stage analytic approach to calculate pooled relative risks.¹⁸ First, we estimated study-specific relative risks (RR) and 95% confidence intervals (CI) between our exposure variables and risk of prostate cancer using the Cox proportional hazard model.³² We adjusted for age and calendar time by stratifying by age at baseline (in years), year of questionnaire return, and center (only EPIC), and treated months since entry into the study until the minimum date of diagnosis of prostate cancer, death (for all fatal cases) or end of study as the time scale.¹⁸ In addition, we adjusted for known or suspected risk factors for prostate cancer either by including these variables in the multivariable model or, for studies with <200 cases, by using the propensity score method^{33–35} (for more detail on covariates included in the final multivariable model, see Table 3). Because pooled multivariable and age-adjusted RRs were similar, only pooled multivariable RRs (MVRR) are presented. Trend tests were conducted by including the median value of each exposure category as a continuous variable in the models. The second stage of the analysis includes calculating pooled RRs employing the random-effects model with studies weighted by the sum of the inverse of the variance and the estimated between-studies variance components.^{36,37} The Q -

statistic^{36,38} and the I^2 statistic³⁹ were used to test for heterogeneity in the study-specific results.

To examine possible effect modification of associations between the main exposure variables and risk of prostate cancer by age at diagnosis, follow-up time and body mass index (BMI), we used mixed effects meta-regression models.⁴⁰

A contrast test was employed to compare associations for prostate cancers by stage and grade.⁴¹ A two-sided p value of 0.05 was considered statistically significant.

Results

During follow-up ranging from 9 to a maximum of 22 years across studies, 52,683 incident prostate cancer cases (stage: 38,445 localized, 4,924 advanced which included 3,199 fatal; grade: 37,530 low and 9,746 high) were identified (Table 1). The proportion of advanced and fatal cases varied considerably across studies, ranging from 2% to 37% for advanced and 1% to 21% for fatal cases. There was also considerable variation across studies with regard to meat and egg intake; differences in the study-specific median intakes ranged from fivefold for poultry to 43-fold for processed meat (Table 2).

In terms of magnitude of associations, we only discuss RRs of at least 1.10 or equal to or below 0.90 (10% difference in risk, when comparing highest vs. lowest category of intake).

Associations between intakes of meat and eggs and total prostate cancer risk were similar to those for localized prostate cancer (Table 3). Higher intake of unprocessed red or processed meat was not associated with a substantially increased risk of total, advanced, low or high-grade cancers. After excluding fatal cases initially diagnosed as localized and those with missing stage at diagnosis from the definition of advanced cases, participants in the highest red and processed meat intake categories had a 17% to 19% increased risk of advanced (total) cancers than those in the lowest category. There was statistically significant heterogeneity between studies in the pooled MVRRs for unprocessed red meat intake and advanced and fatal cancers (heterogeneity test for highest category p value =0.03) with study-specific RRs ranging from 0.33 to 1.51. Differences in geographical region (*i.e.* North-America vs. other continents, Table 4), age at diagnosis (<65 years vs. ≥65 years), or follow-up time (<5 years vs. ≥5 years) did not explain the heterogeneity (all tests for interaction p value ≥0.20).

Poultry intake was associated with a statistically significantly higher risk of localized and low grade cancers but was associated with a statistically significantly lower risk of advanced and fatal cancers (highest vs. lowest category: pooled MVRR: advanced 0.83, 95% CI 0.70–0.99, heterogeneity test for highest category p value 0.16; fatal 0.69, 95% CI 0.59–0.82, heterogeneity test for highest category p value 0.47).

Seafood intake was not significantly associated with risk of prostate cancer regardless of stage or grade. However, there was evidence for heterogeneity between studies in the pooled MVRRs for seafood intake and localized (heterogeneity test for highest category p value 0.06) and low grade cancers (heterogeneity test for highest category p value 0.04).

Heterogeneity due to differences by region was observed for the association with localized

tumors (interaction test p value =0.03) with an 8% increase in risk being observed in the North American studies and a nonsignificant 10% decrease in risk being observed in studies from other continents. Among the studies that assessed fish intake separately from shellfish intake, associations between total fish intake and risk of advanced (advanced, 11 studies, advanced(r), 8 studies) and fatal prostate (9 studies) cancers were similar to those observed for seafood intake (highest vs. lowest category (cutoffs same as for seafood): pooled MVRR, 95% CI: advanced 0.96, 0.83–1.12, trend test p value 0.83; advanced(r) 1.08, 0.89–1.30, trend test p value 0.30; fatal 0.89, 0.74–1.07, trend test p value 0.46).

Participants in the highest category of egg intake (≥ 25 g/day, 1 egg ~50 g) had a 14% increased risk of advanced and fatal cancers when compared with participants in the lowest category (<5 g/day) (pooled MVRR: advanced 1.14, 95% CI 1.01–1.28, heterogeneity test for highest category p value =0.24; fatal 1.14, 95% CI 1.00–1.30, heterogeneity test for highest category p value =0.33).

Despite an absence of statistical heterogeneity for the overall pooled estimate, we (*post hoc*) examined associations between meat and egg intake and risk of advanced, advanced(r) and fatal cancers separately by geographical region as there was a suggestion that study-specific MVRRs may differ by region for some exposures (Table 4). When associations were analyzed separately by geographical region (North America vs. other Continents) red meat and egg intake were positively associated and poultry intake inversely associated with risk of advanced, advanced(r) and fatal cancers in North American studies only. However, only the difference in the results for egg intake and advanced, advanced(r) and fatal cancers were statistically significant (all tests for interaction highest category p value ≤ 0.02). Associations for processed meat and seafood intake did not appear to differ by geographical region.

All participants in the PLCO trial⁵ and the PCPT trial²³ who were included in this study have been screened, *i.e.* underwent Prostate Specific Antigen (PSA) testing prior to study entry. Therefore, associations between our exposures and advanced or fatal cancers were also examined after excluding PLCO from the analysis (PCPT was already excluded in our advanced/fatal analysis due to limited number of cases), but results were essentially unchanged (data not shown).

Associations between poultry and egg intake and risk of advanced, advanced(r) and fatal cancers remained similar after mutual adjustment for processed, unprocessed red meat, poultry (for egg intake only), seafood and egg (for poultry intake only) intake as well as after adding dietary components from meat or egg intake, *i.e.* saturated fat, cholesterol, total iron and protein intake separately to the models (data not shown).

Associations between red meat, processed meat, poultry, seafood and egg intake and risk of localized, advanced, fatal, and low and high-grade prostate cancers did not generally vary significantly by age at diagnosis (<65 vs. ≥ 65 years), follow-up time (<5 vs. ≥ 5 years) or BMI (<25 vs. ≥ 25 kg/m², data not shown) except that the association between poultry and localized cancer differed by BMI (interaction test p value=0.04) and the association between eggs and advanced(r) cancer differed by follow-up time (interaction test p value=0.03).

Discussion

Our results do not support a substantial effect of red and processed meat for all prostate cancer outcomes, except for a modest positive association for tumors identified as advanced at diagnosis. For processed meat and seafood consumption, no substantial association was observed for prostate cancer regardless of stage or grade. Higher poultry intake was associated with a modestly lower risk of advanced and fatal cancers. Higher egg intake was associated with a modestly higher risk of advanced(*r*) and fatal cancers and not associated with risk of localized, low-grade, or high-grade tumors. In addition, our results also suggested differences by geographical region.

Red and processed meat

Epidemiological evidence relating red meat and processed meat intake to prostate cancer risk has been inconsistent.^{1,2,42} Differences in the definition of the prostate cancer outcome variables and limited statistical power to examine metastatic or fatal cancers may, at least in part, explain some of the inconsistencies in results between studies. In our study, we also observed different associations with red and processed meat intake for the two advanced outcomes where modest positive associations were observed only for tumors identified as advanced at diagnosis [advanced(*r*) tumors]. Another possible explanation for the inconsistencies in study results is the varied definition of red and processed meat. For example, some studies examined unprocessed red meat and processed meat separately whereas other studies examined unprocessed red and processed meats in combination,^{1,2} but the type of meat consumed may influence exposure to potential carcinogens. For example, nitrite and nitrate, which can be converted to carcinogenic N-nitroso compounds, are commonly added to processed meats as preservatives^{43,44} (for a general discussion on inconsistencies in study results also refer to Strengths and Limitations).

Poultry and seafood

In our study, higher poultry intake modestly reduced risk of advanced and fatal prostate cancer. The biological mechanisms underlying our findings on poultry intake and risk of fatal cancer are unclear. In the CaPSURETM study, men with a higher intake of poultry with skin after diagnosis had increased prostate cancer progression,⁴⁵ but no association was observed for consumption of poultry without skin. These findings may possibly be due to higher heterocyclic amine content or overall meat derived mutagenicity (compounds associated with certain cooking methods), in chicken eaten with skin versus without skin.⁴⁶ In the California Collaborative Prostate Cancer Study, higher intake of baked poultry, but not grilled, broiled or high-temperature cooked poultry, was associated with lower risk of advanced cancers.⁴⁷

Consuming fish may lower risk of prostate cancer, because fish contains high amounts of omega-3 polyunsaturated fatty acids which have anti-inflammatory properties.⁴⁸ A recent meta-analysis⁴⁸ observed a statistically significant 73% lower risk of prostate cancer mortality comparing the highest *versus* lowest categories of fish intake. However, the results were based on only four cohort studies and there was significant heterogeneity in the results between studies (test for heterogeneity *p* value =0.001). None of the aforementioned four

cohort studies^{49–52} were included in this analysis, because they did not meet our inclusion criteria (for more detail on inclusion criteria please see above under methods). We did not examine associations separately for intakes of dark meat fish, which contain higher amounts of omega-3 fatty acids than white meat fish,⁵³ or individual omega-3 fatty acids because these data generally were not available in the studies that contributed to this analysis.

Eggs

In our study, higher egg intake was significantly associated with a modestly higher risk of advanced and fatal prostate cancer. Four prospective studies,^{11,16,50,54} of which two^{11,16} were included in this analysis, have reported on the association between egg intake and risk of advanced or fatal cancers, but results were inconsistent. While in the Lutheran Brotherhood Cohort Study no association between egg intake and risk of fatal cancers was found,⁵⁰ another study among Seventh-day Adventists observed a 60% higher risk of fatal prostate cancers among participants who ate eggs at least 3 days per week compared to <1 day per week, but the association was not statistically significant (trend test p value =0.09).⁵⁴ The aforementioned two cohort studies were not included in our analysis because both studies did not meet our inclusion criteria (Lutheran Brotherhood Cohort Study: lack of validated dietary instrument; the Seventh-day Adventists Study: <50 incident cases of prostate cancer). In the CaPSURE™ study, higher egg intake was associated with a twofold increase in risk of prostate cancer progression (RR for highest vs. lowest quartile =2.02, 95% CI 1.10–3.72).⁴⁵

The biological mechanisms underlying these positive associations are unknown, but eggs contain considerable amounts of choline.⁵⁵ Choline is crucial for cell membrane synthesis and in prostate cancer cell lines choline kinase, which is involved in the conversion of choline to phosphatidylcholine, is overexpressed compared with normal prostate cell lines.^{55,56} Positive associations between plasma choline⁵⁷ and choline intake¹⁷ and prostate cancer outcomes have also been reported previously.

Associations by geographical region

In our study, positive associations between unprocessed red meat and egg intake and advanced, advanced(r) and fatal cancers were generally observed in North American studies, but not in studies from other continents. However, the heterogeneity observed by region was only statistically significant for egg intake. Unlike in Europe and Australia (regions represented in our pooled analysis), in North America, starting in the mid-90s PSA tests have been increasingly used to screen for prostate cancers which results in cancers being detected at an earlier stage⁵⁸ and we observed that some cancers in our study that were initially diagnosed with a stage of T1 or T2, N0, M0 and thus would be considered “localized” tumors, progressed over time likely due to undetected micro-metastases and became lethal. It is conceivable that in North America, men with an unhealthy lifestyle may be less likely to undergo PSA screening than those with a healthy lifestyle and therefore may be diagnosed at more advanced stages.⁵⁹ Differences in PSA screening may also, at least in part, explain the stronger positive associations we observed for red meat intake with advanced(r) versus advanced tumors. One way to examine whether PSA screening affected our observed associations is to examine associations separately for cases diagnosed in the

“pre and post” PSA eras or to exclude participants with a history of PSA screening. However, we were not able to conduct these analyses, because the majority of the North American studies started after or around the PSA era (post-PSA), we did not have a sufficient number of cases in the “pre-PSA” stratum (*i.e.* cases diagnosed before 1992). Furthermore, information on history of PSA screening was not available for the majority of our studies. Besides differences in prostate cancer screening practices, other explanations such as differences in characteristics of study population or diet assessment may also account for some of the observed differences by geographical region. Further, even though at this point purely speculative, it is also possible that other factors that may differ by geographical region such as meat processing, farming practices, nutrient or preservative content in animal feeds or culinary preference, may at least in part be responsible for our observed associations. In North America, eggs are often consumed with processed meats such as bacon or sausages. However, in our study observed associations between egg intake and advanced, advanced(*r*) and fatal cancers remained similar after mutual adjustment for processed, unprocessed red meat, poultry and seafood intake (data not shown).

Strengths

Besides its prospective design, which minimizes recall and selection bias, other strengths of this study include its large sample size allowing us to examine associations with more statistical power than the individual studies. Also, the wide variation in meat and egg intake across studies enabled us to examine a wider range of intake than in individual studies. Further, we analyzed the primary data from each study and created harmonized exposure and outcome variables, thereby reducing heterogeneity among studies caused by differences in definitions of these variables. Another advantage of this study is the uniform definition of prostate cancer. Previous individual studies have defined “advanced” or “aggressive” cancers inconsistently.³ Some studies used different stage cutoffs (*e.g.* extension beyond prostate (T3N0M0)¹² vs. distant metastases (N1 or M1)⁹), while other studies used a combination of stage and grade to define “aggressive” prostate cancers.^{8,22} However, some risk factors that may lead to progression may be different from those related to high-grade cancers.³

Limitations

Our study also has some limitations. First, associations were examined using only baseline intake data, thus we could not account for changes in intake over time. Secondly, our definitions of specific meat groups may only roughly approximate the true exposure of interest, *e.g.* compounds associated with cooking methods^{60,61} or intakes of nitrite/nitrate.⁴³ In animal studies, PhIP (2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine), the major heterocyclic amine found in human diet,⁶² has been found to increase the rates of prostate cancer in rats.⁶³ However, results from cohort studies that have examined associations between cooking methods or meat-related mutagens and prostate cancer risk in detail are inconclusive.^{5,12,47,64–68} We did not examine intake of meat mutagens, because only a few studies in our analyses had collected detailed information on cooking methods. Thirdly, we cannot exclude the possibility that our findings may reflect associations with certain lifestyle factors related to meat or egg intake. However, we adjusted for known and potential lifestyle

related risk factors for prostate cancer and our age-adjusted and multivariable adjusted models yielded similar results.

In conclusion, our results do not support a substantial association between red and processed meat and all prostate cancer outcomes except for a modest positive association for tumors identified as advanced tumors at diagnosis. For seafood, no substantial association was observed for prostate cancer regardless of stage or grade. Higher poultry intake was associated with a modest lower risk, while higher egg intake was associated with a modest higher risk of fatal cancers. Observed differences in associations by geographical region warrant further investigation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Grant sponsor: National Cancer Institute, National Institutes of Health, USA; **Grant number:** P01 CA55075; **Grant sponsor:** World Cancer Research Fund (WCRF UK), as part of the WCRF International grant programme; **Grant number:** 2009/89

The authors thank the participants and staff of each of the cohorts for their valuable contributions and the organizations that funded each cohort study (see Supplemental Material). The centralization, checking, harmonization, and statistical analyses of the participant level data from each of the cohorts was funded by grant P01 CA55075 from the National Cancer Institute and by grant 2009/89 from the World Cancer Research Fund (WCRF UK), as part of the WCRF International grant programme.

References

1. Dagnelie PC, Schuurman AG, Goldbohm RA, et al. Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. *BJU Int.* 2004; 93:1139–50. [PubMed: 15142129]
2. Alexander DD, Mink PJ, Cushing CA, et al. A review and meta-analysis of prospective studies of red and processed meat intake and prostate cancer. *Nutr J.* 2010; 9:50. [PubMed: 21044319]
3. Giovannucci E, Liu Y, Platz EA, et al. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. *Int J Cancer.* 2007; 121:1571–8. [PubMed: 17450530]
4. Allen NE, Key TJ, Appleby PN, et al. Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. *Br J Cancer.* 2008; 98:1574–81. [PubMed: 18382426]
5. Cross AJ, Peters U, Kirsh VA, et al. A prospective study of meat and meat mutagens and prostate cancer risk. *Cancer Res.* 2005; 65:11779–84. [PubMed: 16357191]
6. Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. *J Natl Cancer Inst.* 1995; 87:1767–76. [PubMed: 7473833]
7. Michaud DS, Augustsson K, Rimm EB, et al. A prospective study on intake of animal products and risk of prostate cancer. *Cancer Causes Control.* 2001; 12:557–67. [PubMed: 11519764]
8. Park SY, Murphy SP, Wilkens LR, et al. Fat and meat intake and prostate cancer risk: the multi-ethnic cohort study. *Int J Cancer.* 2007; 121:1339–45. [PubMed: 17487838]
9. Rodriguez C, McCullough ML, Mondul AM, et al. Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiol Biomarkers Prev.* 2006; 15:211–6. [PubMed: 16492907]
10. Rohrmann S, Platz EA, Kavanaugh CJ, et al. Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study. *Cancer Causes Control.* 2007; 18:41–50. [PubMed: 17315319]

11. Schuurman AG, van den Brandt PA, Dorant E, et al. Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study. *Br J Cancer*. 1999; 80:1107–13. [PubMed: 10362125]
12. Sinha R, Park Y, Graubard BI, et al. Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States. *Am J Epidemiol*. 2009; 170:1165–77. [PubMed: 19808637]
13. Neuhauser ML, Barnett MJ, Kristal AR, et al. (n-6) PUFA increase and dairy foods decrease prostate cancer risk in heavy smokers. *J Nutr*. 2007; 137:1821–7. [PubMed: 17585037]
14. Augustsson K, Michaud DS, Rimm EB, et al. A prospective study of intake of fish and marine fatty acids and prostate cancer. *Cancer Epidemiol Biomarkers Prev*. 2003; 12:64–7. [PubMed: 12540506]
15. Chan JM, Pietinen P, Virtanen M, et al. Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). *Cancer Causes Control*. 2000; 11:859–67. [PubMed: 11075876]
16. Richman EL, Kenfield SA, Stampfer MJ, et al. Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival. *Cancer Prev Res (Phila)*. 2011; 4:2110–21. [PubMed: 21930800]
17. Richman EL, Kenfield SA, Stampfer MJ, et al. Choline intake and risk of lethal prostate cancer: incidence and survival. *Am J Clin Nutr*. 2012; 96:855–63. [PubMed: 22952174]
18. Smith-Warner S, Spiegelman D, Ritz J, et al. Methods for pooling results of epidemiologic studies: the pooling project of prospective studies of diet and cancer. *Am J Epidemiol*. 2006; 163:1053–64. [PubMed: 16624970]
19. Ahn J, Moslehi R, Weinstein SJ, et al. Family history of prostate cancer and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. *Int J Cancer*. 2008; 123:1154–9. [PubMed: 18546266]
20. Larsson SC, Akesson A, Wolk A. Dietary acryl-amide intake and prostate cancer risk in a prospective cohort of Swedish men. *Cancer Epidemiol Biomarkers Prev*. 2009; 18:1939–41. [PubMed: 19505926]
21. Kurahashi N, Inoue M, Iwasaki M, et al. Dairy product, saturated fatty acid, and calcium intake and prostate cancer in a prospective cohort of Japanese men. *Cancer Epidemiol Biomarkers Prev*. 2008; 17:930–7. [PubMed: 18398033]
22. Muller DC, Severi G, Baglietto L, et al. Dietary patterns and prostate cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2009; 18:3126–9. [PubMed: 19861522]
23. Kristal AR, Arnold KB, Neuhauser ML, et al. Diet, supplement use, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. *Am J Epidemiol*. 2010; 172:566–77. [PubMed: 20693267]
24. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. *Biometrika*. 1986; 73:1–11.
25. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr*. 2002; 5:1113–24. [PubMed: 12639222]
26. Thompson FE, Kipnis V, Midthune D, et al. Performance of a food-frequency questionnaire in the US NIH-AARP (National Institutes of Health-American Association of Retired Persons) Diet and Health Study. *Public Health Nutr*. 2008; 11:183–95. [PubMed: 17610761]
27. Flagg EW, Coates RJ, Calle EE, et al. Validation of the American Cancer Society Cancer Prevention Study II nutrition survey cohort food frequency questionnaire. *Epidemiology*. 2000; 11:462–68. [PubMed: 10874556]
28. Messerer M, Johansson SE, Wolk A. The validity of questionnaire-based micronutrient intake estimates is increased by including dietary supplement use in Swedish men. *J Nutr*. 2004; 134:1800–5. [PubMed: 15226472]
29. Tsubono Y, Sasaki S, Kobayashi M, et al. Food composition and empirical weight methods in predicting nutrient intakes from food frequency questionnaire. *Ann Epidemiol*. 2001; 11:213–18. [PubMed: 11248586]

30. Stram DO, Hankin JH, Wilkens LR, et al. Calibration of the dietary questionnaire for a multi-ethnic cohort in Hawaii and Los Angeles. *Am J Epidemiol*. 2000; 151:358–70. [PubMed: 10695594]
31. Subar AF, Thompson FE, Kipnis V, et al. Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires: the Eating at America's Table Study. *Am J Epidemiol*. 2001; 154:1089–99. [PubMed: 11744511]
32. Cox DR. Regression models and life-tables. *J R Stat Soc Ser B*. 1972; 34:187–220.
33. Cepeda MS. The use of propensity scores in pharmacoepidemiologic research. *Pharmacoepidemiol Drug Saf*. 2000; 9:103–4. [PubMed: 19025808]
34. Imai K, Van Dyk D. Causal inference with general treatment regimes: generalizing. The propensity score. *J Am Stat Assoc*. 2004; 99:854–66.
35. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. *Am J Epidemiol*. 1999; 150:327–33. [PubMed: 10453808]
36. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986; 7:177–88. [PubMed: 3802833]
37. Laird NM, Ware JH. Random-effects models for longitudinal data. *Biometrics*. 1982; 38:963–74. [PubMed: 7168798]
38. Cochran WG. The combination of estimates from different experiments. *Biometrics*. 1954; 10:101–29.
39. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ*. 2003; 327:557–60. [PubMed: 12958120]
40. Stram DO. Meta-analysis of published data using a linear mixed-effects model. *Biometrics*. 1996; 52:536–44. [PubMed: 8672702]
41. Anderson, TW. Introduction to multivariate statistics. 2. New York, NY: Wiley; 1984.
42. Kolonel LN. Fat, meat, and prostate cancer. *Epidemiol Rev*. 2001; 23:72–81. [PubMed: 11588857]
43. Cross AJ, Sinha R. Meat-related mutagens/carcinogens in the etiology of colorectal cancer. *Environ Mol Mutagen*. 2004; 44:44–55. [PubMed: 15199546]
44. Cross AJ, Pollock JR, Bingham SA. Haem, not protein or inorganic iron, is responsible for endogenous intestinal N-nitrosation arising from red meat. *Cancer Res*. 2003; 63:2358–60. [PubMed: 12750250]
45. Richman EL, Stampfer MJ, Paciorek A, et al. Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. *Am J Clin Nutr*. 2010; 91:712–21. [PubMed: 20042525]
46. National Cancer Institute. [Last accessed date 21 January 2016] CHARRED: Computerized Heterocyclic Amines Database Resource for Research in Epidemiologic of Disease. 2006. Available at: <http://dceg.cancer.gov/neb/tools/charred>
47. Joshi AD, Corral R, Catsburg C, et al. Red meat and poultry, cooking practices, genetic susceptibility and risk of prostate cancer: results from a multiethnic case-control study. *Carcinogenesis*. 2012; 33:2108–18. [PubMed: 22822096]
48. Szymanski KM, Wheeler DC, Mucci LA. Fish consumption and prostate cancer risk: a review and meta-analysis. *Am J Clin Nutr*. 2010; 92:1223–33. [PubMed: 20844069]
49. Chavarro JE, Stampfer MJ, Hall MN, et al. A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality. *Am J Clin Nutr*. 2008; 88:1297–303. [PubMed: 18996866]
50. Hsing AW, McLaughlin JK, Schuman LM, et al. Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. *Cancer Res*. 1990; 50:6836–40. [PubMed: 2208150]
51. Pham TM, Fujino Y, Kubo T, et al. Fish intake and the risk of fatal prostate cancer: findings from a cohort study in Japan. *Public Health Nutr*. 2009; 12:609–13. [PubMed: 18664313]
52. Terry P, Lichtenstein P, Feychting M, et al. Fatty fish consumption and risk of prostate cancer. *Lancet*. 2001; 357:1764–6. [PubMed: 11403817]
53. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation*. 2002; 106:2747–57. [PubMed: 12438303]

54. Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. *Am J Epidemiol.* 1984; 120:244–50. [PubMed: 6465122]
55. U.S. Department of Agriculture, Agricultural Research Service. Nutrient Data Laboratory Home Page. U.S. Department of Agriculture, Agricultural Research Service; Washington, DC 20250: 2010. USDA National Nutrient Database for Standard Reference, Release 23. Available at: <http://www.ars.usda.gov/ba/bhnrc/ndl> [Last accessed date 21 January 2016]
56. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. *Biochem Biophys Res Commun.* 2002; 296:580–3. [PubMed: 12176020]
57. Johansson M, Van Guelpen B, Vollset SE, et al. One-carbon metabolism and prostate cancer risk: prospective investigation of seven circulating B vitamins and metabolites. *Cancer Epidemiol Biomarkers Prev.* 2009; 18:1538–43. [PubMed: 19423531]
58. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. *CA Cancer J Clin.* 2010; 60:70–98. [PubMed: 20200110]
59. Mucci, L.A.; Giovannucci, E. The role of diet and nutrition in prostate cancer. In: Bendich, ADR., editor. *Preventive nutrition.* 4. Totowa, NJ: Humana Press; 2010. p. 195-218.
60. Sugimura T, Wakabayashi K, Nakagama H, et al. Heterocyclic amines: mutagens/carcinogens produced during cooking of meat and fish. *Cancer Sci.* 2004; 95:290–9. [PubMed: 15072585]
61. Sinha R. An epidemiologic approach to studying heterocyclic amines. *Mutat Res.* 2002; 506:197–204. [PubMed: 12351159]
62. Schut HA, Snyderwine EG. DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. *Carcinogenesis.* 1999; 20:353–68. [PubMed: 10190547]
63. Shirai T, Sano M, Tamano S, et al. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. *Cancer Res.* 1997; 57:195–8. [PubMed: 9000552]
64. Koutros S, Cross AJ, Sandler DP, et al. Meat and meat mutagens and risk of prostate cancer in the Agricultural Health Study. *Cancer Epidemiol Biomarkers Prev.* 2008; 17:80–7. [PubMed: 18199713]
65. Koutros S, Berndt SI, Sinha R, et al. Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. *Cancer Res.* 2009; 69:1877–84. [PubMed: 19223546]
66. Sander A, Linseisen J, Rohrmann S. Intake of heterocyclic aromatic amines and the risk of prostate cancer in the EPIC-Heidelberg cohort. *Cancer Causes Control.* 2011; 22:109–14. [PubMed: 21103922]
67. Sharma S, Cao X, Wilkens LR, et al. Well-done meat consumption, NAT1 and NAT2 acetylator genotypes and prostate cancer risk: the multiethnic cohort study. *Cancer Epidemiol Biomarkers Prev.* 2010; 19:1866–70. [PubMed: 20570911]
68. Punnen S, Hardin J, Cheng I, et al. Impact of meat consumption, preparation, and mutagens on aggressive prostate cancer. *PLoS One.* 2011; 6:e27711. [PubMed: 22132129]

What's new?

The debate over red meat consumption and cancer risk is longstanding. In this consortium of 15 cohorts from North America, Europe, Australia and Asia, the authors examined over 50,000 cases of prostate cancer and the associated intake of unprocessed red and processed meat, seafood, eggs and poultry. Overall no substantial risk for unprocessed red and processed meat intake and prostate cancer was found. Interestingly, positive associations between intake of unprocessed red meat as well as eggs and advanced or fatal prostate cancers were detected only in participants living in North America, a finding which warrants further investigation into meat and egg composition, consumption and potential differences in lifestyle and screening practices between continents.

Table 1

Characteristics of the studies included in the pooled analysis of meat and prostate cancer

Study	Country/continent	Follow-up	Baseline cohort size	Age range (yr)	Total cases	Localized cases	Advanced cases (% ¹)	Advanced (restricted) cases (% ¹)	Fatal cases (%)	Low grade cases	High grade cases (% ²)
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study	Finland	1985–2002	26,987	50–69	1,316	828	354 (37)	243 (19)	270 (21)	825	223 (21)
Beta-Carotene and Retinol Efficacy Trial	USA	1985–2005	10,474	50–69	736	442	68 (11)	45 (8)	38 (6)	555	79 (12)
CLUE II: Campaign Against Cancer and Heart Disease	USA	1989–2009	5,926	18–90	461	250	54 (14)	25 (6)	46 (12)	296	133 (31)
Cancer Prevention Study-II Nutrition Cohort	USA	1992–2005	65,923	50–74	6,943	5,785	458 (7)	282 (4)	283 (4)	5,433	1,238 (19)
Cohort of Swedish Men	Sweden	1998–2008	45,338	45–79	3,014	1,853	538 (18)	398 (14)	310 (11)	1,726	365 (17)
European Investigation into Cancer and Nutrition	Europe	1991–2006	142,195	20–97	2,727	1,337	345 (17)	175 (9)	248 (12)	1,325	298 (18)
Health Professionals Follow-Up Study	USA	1986–2008	47,781	40–75	5,536	3,879	669 (13)	321 (6)	532 (10)	4,094	571 (12)
The Japan Public Health Center- Based Study Cohort 1	Japan	1990–2004	20,161	40–59	135	78	20 (19)	16 (15)	5 (5)	90	34 (27)
The Japan Public Health Center- Based Study Cohort 2	Japan	1993–2004	24,116	40–69	167	84	38 (27)	32 (23)	12 (9)	92	46 (33)
Melbourne Collaborative Cohort Study	Australia	1990–2006	14,824	27–75	910	737	76 (9)	11 (1)	70 (8)	668	218 (25)
Multietnic Cohort Study	USA	1993–2004	84,297	45–75	5,583	4,597	512 (10)	367 (7)	283 (5)	3,668	1,575 (30)
The Netherlands Cohort Study	Netherlands	1986–2007	58,279	55–69	2,416	1,263	749 (33)	557 (24)	460 (20)	1,746	500 (22)
The NIH-AARP Diet and Health Study	USA	1995–2006	250,065	50–71	18,889	13,946	886 (5)	540 (3)	554 (3)	13,744	3,964 (22)
Prostate Cancer Prevention Trial	USA	1994–2003	15,620	55–86	853	792	13 (2)	8 (1)	7 (1)	684	107 (14)
The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial	USA	1993–2008	30,163	55–74	2,997	2,574	144 (5)	90 (3)	81 (3)	2,584	395 (13)
Total			842,149		52,683	38,445	4,924	3,110	3,199	37,530	9,746

¹“Localized”: defined as cancers with information on stage but are not defined as “periprostatic”, i.e. cancers confined within the prostate; “Advanced”: defined as T4, N1, M1 or fatal cancers. “advanced (restricted)”: same as “advanced” but excluding localized cases and cases with missing stage, who died of prostate cancer during follow-up; “low grade”: gleason score <8 or well/moderately differentiated; “high grade”: gleason score ≥8 or poorly differentiated/undifferentiated.

²Percentages calculated using total number of cases with non-missing data on stage, therefore numbers do not add to 100%.

³Percentages calculated using total number of cases with non-missing data on grade, therefore numbers do not add up to 100%.

Table 2

Median intake of dietary factors by studies (10th–90th percentile)¹

Study	Unprocessed red meat (g/d)	Processed meat (g/d)	Poultry (g/d)	Seafood (g/d) ²	Eggs (g/d)
Alpha-Tocopherol, Beta- Carotene Cancer Prevention Study	65.1 (35.9–113)	60.2 (22.2–142)	7.95 (0.00–30.4)	32.5 (11.4–74.5)	44.6 (18.1–96.9)
Beta-Carotene and Retinol Efficacy Trial	44.9 (15.8–106)	16.1 (2.79–51.4)	13.5 (3.37–39.2)	17.6 (2.31–46.4)	13.3 (0.00–46.7)
CLUE II: Campaign Against Cancer and Heart Disease	37.1 (8.58–93.6)	17.9 (1.65–57.2)	15.4 (3.47–41.8)	11.1 (0.00–30.7)	12.5 (0.00–46.7)
Cancer Prevention Study-II Nutrition Cohort	44.2 (12.8–103)	13.1 (0.00–45.6)	20.57 (6.00–50.0)	17.1 (3.34–45.3)	8.36 (0.00–28.6)
Cohort of Swedish Men	55.7 (23.3–88.9)	32.8 (10.2–66.1)	8.87 (7.56–25.0)	30.4 (12.7–61.6)	15.3 (4.82–36.2)
European Investigation into Cancer and Nutrition	49.6 (8.55–114)	31.8 (2.37–88.3)	15.7 (0.37–49.5)	27.8 (4.11–78.2)	15.3 (3.50–42.5)
Health Professionals Follow-Up Study	56.4 (18.1–134)	6.80 (0.00–22.6)	39.2 (19.6–79.8)	32.6 (8.96–84.4)	7.00 (0.00–40.0)
The Japan Public Health Center-Based Study Cohort 1	21.0 (10.3–35.3)	4.71 (0.00–11.0)	10.7 (0.00–25.0)	41.4 (21.4–104)	25.0 (10.7–50.0)
The Japan Public Health Center-Based Study Cohort 2	10.3 (3.36–24.0)	1.40 (0.00–4.28)	9.42 (3.08–22.0)	53.0 (14.4–115)	25.0 (3.50–50.0)
Melbourne Collaborative Cohort Study	109 (39.2–235)	21.4 (2.80–58.7)	24.0 (8.40–66.0)	23.5 (8.40–61.0)	17.5 (0.00–49.4)
Multietnic Cohort Study	55.0 (12.0–146)	14.6 (2.90–46.3)	36.3 (11.3–101)	18.4 (3.58–54.4)	11.5 (2.88–39.1)
The Netherlands Cohort Study	63.8 (31.6–107)	15.3 (2.90–42.0)	10.6 (0.00–18.2)	11.5 (0.00–33.9)	14.2 (7.10–28.5)
The NIH-AARP Diet and Health Study	38.7 (9.01–108)	16.7 (3.65–53.1)	24.4 (5.81–77.6)	14.7 (3.74–48.7)	10.7 (0.00–25.0)
Prostate Cancer Prevention Trial	40.7 (7.92–116)	8.29 (0.53–33.5)	29.8 (6.87–93.1)	24.2 (3.57–72.3)	7.36 (0.00–47.3)
The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial	56.0 (16.7–143)	15.5 (3.25–51.1)	18.1 (4.07–60.7)	21.7 (5.60–66.4)	12.1 (1.40–42.5)

¹ Definition of meat and fish variables: unprocessed red meat included all unprocessed red meats such as beef, pork, lamb and veal but excluding organs; processed meat included all processed meats such as sausages, hot dogs, bacon, ham and luncheon meats; poultry included unprocessed meats from birds such as chicken and turkey; seafood included fish and shellfish but excluding fish organs or roe.

² In the Japan Public Health Center-Based Study Cohort 1 and 2 fish intake was measured with shellfish on the FFQ, fish intake was only assessed separately for dry fish, small fish and fish paste intake. In the NIH-AARP Diet and Health Study one question combined shellfish and other fish on the FFQ, fish intake was only assessed separately for tuna and fried fish. Four studies (Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, CLUE II: Campaign Against Cancer and Heart Disease, Cancer Prevention Study-II Nutrition Cohort and the Netherlands Cohort Study) did not assess shellfish intake therefore seafood intake represents fish intake.

Table 3

Pooled multivariable relative risks (RR)^f and 95% confidence intervals (95% CI) for meat and egg consumption and prostate cancer risk

	Categories (g/d) ²				<i>p</i> value, test of trend	<i>p</i> value, test of between-studies heterogeneity, highest category	<i>I</i> ² , highest category	<i>p</i> value, test of common effects, highest category
	<20	20–<40	40–<80	80–<120				
Total red meat	<20	20–<40	40–<80	80–<120	120			
Total	0.96 (0.92–0.99)	1.00	0.97 (0.93–1.02)	1.00 (0.97–1.03) ^{3,4}	0.99 (0.94–1.03) ^{3,4}	0.19	0.23	24%
<i>By stage</i>								
Localized	0.96 (0.92–0.99)	1.00	0.99 (0.95–1.03)	1.00 (0.97–1.04) ^{3,4}	1.00 (0.96–1.04) ^{3,4}	0.20	0.74	0%
Advanced ⁵	0.96 (0.85–1.09)	1.00	1.01 (0.92–1.11)	0.99 (0.88–1.10)	1.04 (0.89–1.21)	0.63	0.17	29%
Advanced (restricted) ⁶	0.93 (0.79–1.11)	1.00	1.05 (0.92–1.19)	1.05 (0.91–1.21)	1.18 (1.01–1.38)	0.26	0.89	0%
Fatal ⁷	1.03 (0.88–1.21) ^{1,5}	1.00	0.97 (0.86–1.10)	0.98 (0.85–1.14)	1.00 (0.81–1.24)	0.59	0.08	43%
<i>By grade</i>								
Low	0.95 (0.92–0.99)	1.00	0.99 (0.96–1.03)	1.01 (0.97–1.04) ^{3,4}	1.01 (0.97–1.06) ^{3,4}	0.05	0.67	0%
High ⁸	0.94 (0.87–1.01) ^{1,5}	1.00	0.96 (0.90–1.02)	0.97 (0.90–1.04)	0.93 (0.86–1.01)	0.57	0.56	0%
Unprocessed red meat	<20	20–<40	40–<60	60–<100	100			
Total	1.00	1.02 (0.98–1.06)	1.02 (0.99–1.05)	1.02 (0.99–1.06) ⁴	1.02 (0.98–1.06) ^{3,4}	0.93	0.43	2%
<i>By stage</i>								
Localized	1.00	1.01 (0.97–1.07)	1.02 (0.99–1.06)	1.03 (0.99–1.07) ⁴	1.02 (0.97–1.06) ^{3,4}	0.51	0.53	0%
Advanced ⁵	1.00	1.02 (0.91–1.14)	1.00 (0.88–1.14)	0.97 (0.83–1.13)	1.02 (0.83–1.24)	0.56	0.03	52%
Advanced (restricted) ⁶	1.00	1.02 (0.89–1.16)	1.11 (0.96–1.27)	1.05 (0.91–1.21)	1.19 (1.01–1.40)	0.07	0.47	0%
Fatal ⁷	1.00	0.94 (0.81–1.09)	0.95 (0.83–1.08)	0.93 (0.79–1.11)	0.99 (0.78–1.26)	0.66	0.03	53%
<i>By grade</i>								
Low	1.00	1.01 (0.96–1.08)	1.02 (0.99–1.06)	1.03 (0.99–1.07) ⁴	1.03 (0.99–1.08) ^{3,4}	0.30	0.67	0%
High ⁸	1.00	1.00 (0.90–1.11)	0.99 (0.91–1.08)	1.01 (0.92–1.11)	0.93 (0.81–1.06)	0.58	0.09	42%
Processed meat⁹	<5	5–<10	10–<20	20–<40	40			
								0.14 ^{1,3}

	Categories (g/d) ²				<i>p</i> value, test of common effects, highest category	<i>p</i> value, test of between-studies heterogeneity, highest category	<i>I</i> ² , highest category
	1.03 (1.00-1.06)	1.03 (0.99-1.07)	1.03 (0.98-1.08)	1.04 (1.01-1.08)			
Total	1.00	1.03 (0.99-1.06)	1.03 (0.98-1.08)	1.04 (1.01-1.08)	0.29	0.61	0%
<i>By stage</i>							
Localized	1.00	1.03 (0.99-1.06)	1.03 (0.99-1.08)	1.04 (1.00-1.09)	0.11	0.77	0%
Advanced ⁵	1.00	1.06 (0.95-1.18)	1.17 (1.06-1.30)	1.09 (0.95-1.26)	0.55	0.39	7%
Advanced (restricted) ⁶	1.00	1.06 (0.93-1.22)	1.16 (1.02-1.32)	1.04 (0.90-1.20)	0.10	0.94	0%
Fatal ⁷	1.00	1.06 (0.93-1.20)	1.15 (1.02-1.30)	1.04 (0.88-1.24)	0.63	0.51	0%
<i>By grade</i>							
Low	1.00	1.04 (1.00-1.08)	1.04 (1.00-1.08)	1.06 (1.01-1.10)	0.17	0.87	0%
High ⁸	1.00	1.03 (0.96-1.10)	0.98 (0.91-1.05)	1.01 (0.90-1.14)	0.75	0.20	29%
Poultry	<5	5-<15	15-<25	25-<45	45		
Total	1.00	1.01 (0.97-1.05)	1.03 (0.97-1.10) ³	1.01 (0.95-1.07)	0.33	0.55	0%
<i>By stage</i>							
Localized	1.00	1.03 (0.97-1.09)	1.07 (1.00-1.14) ³	1.04 (0.97-1.11)	0.26	0.75	0%
Advanced ⁵	1.00	0.91 (0.82-1.00)	0.84 (0.75-0.94)	0.79 (0.69-0.90)	0.29	0.16	30%
Advanced (restricted) ⁶	1.00	0.98 (0.86-1.11)	0.86 (0.75-1.00)	0.83 (0.70-0.99)	0.44	0.28	19%
Fatal ⁷	1.00	0.83 (0.72-0.96)	0.79 (0.65-0.95)	0.72 (0.62-0.85)	0.16	0.47	0%
<i>By grade</i>							
Low	1.00	1.02 (0.97-1.08)	1.04 (0.97-1.11) ³	1.03 (0.95-1.11)	0.66	0.78	0%
High ⁸	1.00	0.97 (0.90-1.06)	1.00 (0.92-1.09)	0.96 (0.88-1.06)	0.33	0.71	0%
Seafood	<5	5-<10	10-<20	20-<40	40		
Total	1.00	1.05 (1.00-1.11) ³	1.05 (1.01-1.08)	1.05 (1.02-1.09)	0.67	0.22	25%
<i>By stage</i>							
Localized ⁴	1.00	1.04 (1.00-1.08) ³	1.06 (1.01-1.11)	1.07 (1.03-1.11)	0.38	0.06	46%
Advanced ⁵	1.00	1.07 (0.95-1.21)	0.98 (0.88-1.08)	0.97 (0.87-1.09)	0.73	0.73	0%

		Categories (g/d) ²		<i>p</i> value, test of trend	<i>p</i> value, test of between-studies heterogeneity, highest category	<i>I</i> ² , highest category	<i>p</i> value, test of common effects, highest category
Advanced (restricted) ⁶	1.00	1.09 (0.93–1.27)	1.02 (0.90–1.17)	1.01 (0.83–1.22)	1.04 (0.88–1.22)	0%	0.98 /1
Fatal ⁷	1.00	1.05 (0.90–1.22)	0.90 (0.77–1.04)	0.93 (0.80–1.10)	0.87 (0.72–1.06)	24%	0.10 /2
<i>By grade</i>							
Low /4	1.00	1.07 (1.01–1.13) ³	1.07 (1.02–1.12)	1.06 (1.02–1.10)	1.02 (0.94–1.09)	49%	
High ⁸	1.00	1.01 (0.94–1.09)	1.00 (0.93–1.07)	1.04 (0.95–1.14)	1.03 (0.95–1.12)	0%	0.80 /3
Eggs							
<5		5–<25	25				
Total	1.00	1.01 (0.99–1.03)	0.99 (0.96–1.02)			0%	
<i>By stage</i>							
Localized	1.00	1.01 (0.98–1.03)	0.97 (0.94–1.00)			0%	
Advanced ⁵	1.00	1.05 (0.98–1.14)	1.14 (1.01–1.28)			23%	0.009 /0
Advanced (restricted) ⁶	1.00	1.06 (0.95–1.18)	1.07 (0.89–1.29)			50%	0.30 /1
Fatal ⁷	1.00	1.02 (0.93–1.13)	1.14 (1.00–1.30)			13%	0.02 /2
<i>By grade</i>							
Low	1.00	0.99 (0.97–1.02)	0.97 (0.94–1.00)			0%	
High ⁸	1.00	1.08 (1.00–1.17)	1.06 (0.98–1.15)			18%	0.03 /3

¹“Localized”: defined as cancers with information on stage but are not defined as “periprostatic,” i.e. cancers confined within the prostate; “advanced”: defined as T4, N1, M1 or fatal cancers. “advanced (restricted)”: same as “advanced” but excluding localized cases and cases with missing stage, who died of prostate cancer during follow-up; “low grade”: gleason score <8 or well/moderately differentiated; “high grade”: gleason score 8 or poorly differentiated/undifferentiated.

²All multivariable models were adjusted for marital status (married (reference (ref)), never married, widowed, divorced), race (Caucasian (ref), African-American, Asian, Hispanic, other), education (<high school (ref), high school, >high school), body mass index (BMI, kg/m²) (<23 (ref), 23–<25, 25–<30, 30), height (meter) (<1.70 (ref), 1.70–<1.75, 1.75–<1.80, 1.80–<1.85, 1.85), alcohol (g/day) (0 (ref), >0–<5, 5–<15, 15–<30, 30), total energy intake (kcal/d, as continuous variable), smoking status (never (ref), past smoker <15 pack years, past smoker 15 pack years, current smoker <40 pack years, current smoker 40 pack years), prostate cancer family history (no (ref), yes), physical activity (low (ref), medium, high), history of diabetes (no (ref), yes), multivitamin use (no (ref), yes). Age in years and year of questionnaire return were included as stratification variables.

³Grams vs. ounces: 5 g/d = 0.18 ounces/day; 10 g/day = 0.35 ounces/day; 25 g/d = 0.88 ounces/d; 40 g/d = 1.41 ounces/d; 100 g/d = 3.52 ounces/d; 120 g/d = 4.23 ounces/d; 1 egg about 50 g (1.76 ounces); 25 g/d about half an egg per day.

⁴The Japan Public Health Center Study 1 was excluded from this category because this study did not have any cases in this category. The participants in this study who were in this category and were not cases were included in the next highest category. For poultry and seafood no participants were in this category.

- 4⁴The Japan Public Health Center Study 2 was excluded from this category because this study did not have any cases in this category. The participants in this study who were in this category and were not cases were included in the next highest category.
- 5⁵The Japan Public Health Center Study 1, the Japan Public Health Center Study 2 and the Prostate Cancer Prevention Trial were excluded from these analyses because these studies had <50 advanced prostate cancer cases.
- 6⁶The Beta-Carotene Retinol Efficacy Trial, CLUE II: Campaign Against Cancer and Heart Disease, Japan Public Health Center Study 1, the Japan Public Health Center Study 2, Melbourne Collaborative Cohort Study, and the Prostate Cancer Prevention Trial were excluded from these analyses because these studies had <50 advanced (restricted) prostate cancer cases. For egg intake: the Alpha-Tocopherol Beta-Carotene Prevention Study was excluded from this analysis because this study did not have any cases in the reference group.
- 7⁷The Beta-Carotene Retinol Efficacy Trial, CLUE II: Campaign Against Cancer and Heart Disease, Japan Public Health Center Study 1, the Japan Public Health Center Study 2 and the Prostate Cancer Prevention Trial were excluded from these analyses because these studies had <50 fatal prostate cancer cases.
- 8⁸The Japan Public Health Center Study 1 and 2 were excluded from the analyses of high grade cancers because these studies had <50 high grade cancer cases.
- 9⁹The Japan Public Health Center Study 1 and 2 were excluded from the analyses of processed meat consumption due to low consumption.
- 10¹⁰Test for common effects: localized vs. advanced cancers.
- 11¹¹Test for common effects: localized vs. advanced (restricted) cancers.
- 12¹²Test for common effects: localized vs. fatal cancers.
- 13¹³Test for common effects: low grade vs. high grade cancers.
- 14¹⁴The Japan Public Health Center Study 2 was excluded from the analyses of localized and low grade cancers because this study had no cases in the reference group.
- 15¹⁵The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study was excluded from this category because this study did not have any cases in this category.

Table 4

Pooled multivariable relative risks (RR)¹ and 95% confidence intervals (95% CI) for meat and egg consumption and prostate cancer risk by geographic region

	Categories (g/d) ²					p values for test of between-studies heterogeneity, highest category	p values for test of interaction, highest category
	<20	20-<40	40-<60	60-<100	100		
Unprocessed red meat							
Advanced³							
North America	1.00	1.07 (0.96-1.20)	1.07 (0.94-1.22)	1.08 (0.96-1.23)	1.19 (1.02-1.39)	0.01	0.70
Other continents	1.00	0.86 (0.64-1.16)	0.85 (0.60-1.22)	0.76 (0.52-1.11)	0.82 (0.54-1.26)	0.25	0.02
Advanced (restricted)⁴							
North America	1.00	1.05 (0.90-1.22)	1.15 (0.98-1.36)	1.10 (0.93-1.30)	1.30 (1.07-1.57)	0.01	0.78
Other continents	1.00	0.93 (0.73-1.19)	1.01 (0.78-1.29)	0.95 (0.74-1.22)	0.96 (0.70-1.33)	0.82	0.35
Fatal⁵							
North America	1.00	1.01 (0.87-1.16)	1.00 (0.85-1.17)	1.03 (0.88-1.21)	1.12 (0.85-1.46)	0.18	0.20
Other continents	1.00	0.82 (0.59-1.14)	0.84 (0.62-1.13)	0.78 (0.53-1.14)	0.84 (0.54-1.29)	0.37	0.09
Processed meat							
Advanced³							
North America	1.00	1.05 (0.92-1.20)	1.19 (1.06-1.33)	0.95 (0.84-1.08)	1.07 (0.86-1.34)	0.93	0.17
Other continents	1.00	1.12 (0.88-1.42)	1.13 (0.92-1.40)	1.24 (1.00-1.53)	1.12 (0.87-1.45)	0.55	0.62
Advanced (restricted)⁴							
North America	1.00	1.02 (0.87-1.19)	1.16 (0.98-1.37)	0.95 (0.81-1.13)	1.16 (0.95-1.42)	0.18	0.76
Other continents	1.00	1.24 (0.93-1.65)	1.18 (0.91-1.54)	1.29 (0.99-1.69)	1.20 (0.87-1.65)	0.40	0.78
Fatal⁵							
North America	1.00	1.05 (0.91-1.22)	1.16 (1.00-1.36)	0.97 (0.83-1.14)	1.02 (0.76-1.36)	0.99	0.19
Other continents	1.00	1.07 (0.81-1.42)	1.13 (0.88-1.46)	1.29 (1.00-1.67)	1.11 (0.82-1.51)	0.56	0.78
Poultry							
Advanced³							
North America	1.00	0.86 (0.74-1.01)	0.78 (0.67-0.92)	0.75 (0.64-0.88)	0.77 (0.59-1.00)	0.42	0.10

	Categories (g/d) ²					p values for test of trend	p values for test of between-studies heterogeneity, highest category	p values for test of interaction, highest category
	<5	5-<10	10-<20	20-<40	40			
Other continents	1.00	0.94 (0.82-1.07)	0.89 (0.76-1.04)	0.86 (0.69-1.06)	0.92 (0.73-1.17)	0.56	0.52	
Advanced (restricted)⁴								
North America	1.00	1.01 (0.81-1.25)	0.87 (0.70-1.09)	0.83 (0.66-1.04)	0.89 (0.69-1.15)	0.51	0.33	0.55
Other continents	1.00	0.96 (0.83-1.12)	0.86 (0.71-1.03)	0.84 (0.63-1.10)	1.12 (0.79-1.58)	0.71	0.25	
Fatal⁵								
North America	1.00	0.71 (0.58-0.86)	0.65 (0.53-0.79)	0.65 (0.53-0.80)	0.63 (0.51-0.78)	0.23	0.38	0.10
Other continents	1.00	0.94 (0.81-1.10)	0.97 (0.81-1.16)	0.87 (0.67-1.13)	0.85 (0.63-1.14)	0.54	0.78	
Seafood								
<5		5-<10	10-<20	20-<40	40			
Advanced³								
North America	1.00	1.06 (0.92-1.22)	1.00 (0.88-1.15)	0.91 (0.79-1.04)	0.89 (0.76-1.04)	0.11	0.48	0.72
Other continents	1.00	1.10 (0.86-1.40)	0.93 (0.78-1.11)	1.13 (0.93-1.37)	1.04 (0.82-1.31)	0.12	0.88	
Advanced (restricted)⁴								
North America	1.00	1.08 (0.90-1.30)	1.01 (0.85-1.20)	0.91 (0.72-1.17)	0.97 (0.79-1.19)	0.52	0.59	0.34
Other continents	1.00	1.10 (0.82-1.49)	1.04 (0.85-1.28)	1.21 (0.96-1.52)	1.18 (0.89-1.55)	0.04	0.73	
Fatal⁵								
North America	1.00	1.03 (0.85-1.24)	0.94 (0.76-1.17)	0.84 (0.71-1.00)	0.81 (0.61-1.08)	0.05	0.13	0.11
Other continents	1.00	1.15 (0.85-1.56)	0.86 (0.69-1.07)	1.10 (0.85-1.42)	1.02 (0.77-1.35)	0.26	0.73	
Eggs								
<5		5-<25	25					
Advanced³								
North America	1.00	1.13 (1.03-1.24)	1.27 (1.14-1.42)			<0.001	0.60	0.003
Other continents	1.00	0.88 (0.76-1.02)	0.92 (0.77-1.11)			0.88	0.96	
Advanced (restricted)⁴								
North America	1.00	1.15 (1.02-1.30)	1.23 (1.02-1.48)			0.03	0.23	<0.001
Other continents	1.00	0.84 (0.66-1.08)	0.84 (0.67-1.05)			0.23	0.99	
Fatal⁵								
North America	1.00	1.10 (0.98-1.23)	1.26 (1.10-1.45)			0.006	0.50	0.02
Other continents	1.00	0.83 (0.65-1.06)	0.88 (0.73-1.07)			0.80	0.91	

“Localized”: defined as cancers with information on stage but are not defined as “periprostatic,” *i.e.* cancers confined within the prostate; “advanced”: defined as T4, N1, M1 or fatal cancers. “advanced (restricted)”: same as “advanced” but excluding localized cases and cases with missing stage, who died of prostate cancer during follow-up; “low grade”: gleason score <8 or well/moderately differentiated; “high grade”: gleason score ≥ 8 or poorly differentiated/undifferentiated.

¹ All multivariable models were adjusted for marital status (married (reference (ref)), never married, widowed, divorced), race (Caucasian (ref), African-American, Asian, Hispanic, other), education (<high school (ref), high school, >high school), body mass index (BMI, kg/m²) (<23 (ref), 23–<25, 25–<30, 30), height (meter) (<1.70 (ref), 1.70–<1.75, 1.75–<1.80, 1.80–<1.85, 1.85), alcohol (g/day) (0 (ref), >0–<5, 5–<15, 15–<30, 30), total energy intake (kcal/d, as continuous variable), smoking status (never (ref), past smoker <15 pack years, past smoker ≥15 pack years, current smoker <40 pack years, current smoker ≥40 pack years), prostate cancer family history (no (ref), yes), physical activity (low (ref), medium, high), history of diabetes (no (ref), yes), multivitamin use (no (ref), yes). Age in years and year of questionnaire return were included as stratification variables.

² Grams vs. ounces: 5 g/d =0.18 ounces/d; 10 g/d =0.35 ounces/d; 25 g/d =0.88 ounces/d; 40 g/d =1.41 ounces/d; 100 g/d =3.52 ounces/d; 120 g/d =4.23 ounces/d; 1 egg about 50 g (1.76 ounces); 25 g/day about half an egg per day.

³ The Japan Public Health Center Study 1, the Japan Public Health Center Study 2, and the Prostate Cancer Prevention Trial were excluded from these analyses because these studies had <50 advanced prostate cancer cases.

⁴ The Beta-Carotene Retinol Efficacy Trial, CLUE II: Campaign Against Cancer and Heart Disease, the Japan Public Health Center Study 1, the Japan Public Health Center Study 2, the Prostate Cancer Prevention Trial and the Melbourne Collaborative Cohort Study were excluded from these analyses because these studies had <50 advanced (restricted) prostate cancer cases. For egg intake: the Alpha-Tocopherol Beta-Carotene Prevention Study was also excluded from this analysis because this study did not have any cases in the reference group for egg intake.

⁵ The Beta-Carotene Retinol Efficacy Trial, CLUE II: Campaign Against Cancer and Heart Disease, the Japan Public Health Center Study 1, the Japan Public Health Center Study 2, and the Prostate Cancer Prevention Trial were excluded from these analyses because these studies had <50 fatal prostate cancer cases.